Blood Clot "Very Rare" Side Effect Of Johnson & Johnson Vaccine: EU Agency

Europe's Johnson & Johnson campaign was delayed after US health regulators said the shot should be paused over blood clot fears.

Europe's medicines regulator said Tuesday that blood clots should be listed as a "very rare" side effect of Johnson & Johnson's coronavirus vaccine, but that the benefits of the shot still outweighed the risks. The United States is expected to announce its decision on the single-shot J&J vaccine by Friday, as nations around the world urgently try to accelerate inoculation campaigns and revive their pandemic-ravaged economies. The European Medicines Agency (EMA) assessment came as an EU official promised to have enough doses available to vaccinate 70 percent of European adults by the summer -- a boon for the continent's sluggish rollout. Europe's Johnson & Johnson campaign was delayed after US health regulators said the shot should be paused over blood clot fears.